tiprankstipranks
Trending News
More News >
VolitionRX Ltd. (VNRX)
:VNRX
US Market
Advertisement

VolitionRX (VNRX) AI Stock Analysis

Compare
482 Followers

Top Page

VNRX

VolitionRX

(NYSE MKT:VNRX)

Rating:54Neutral
Price Target:
$1.00
▲(35.14%Upside)
VolitionRX's overall stock score is driven primarily by its significant financial challenges, which heavily weigh down the score. However, positive technical trends and an optimistic earnings call with strategic advancements provide some counterbalance. The lackluster valuation further impacts the score, highlighting the company's high-risk profile.
Positive Factors
Innovation
VolitionRx demonstrated quantification of nucleosomes in whole venous blood in minutes using a lateral flow device, showcasing early detection of immune disruptions.
Partnerships
The anticipated announcement of a partnership in the human health space is seen as the most important catalyst, potentially providing non-dilutive capital and validating the business strategy.
Revenue Growth
Revenue grew 44% in 1Q25, with licensing deals expected to boost financial performance.
Negative Factors
Licensing Challenges
Failure to secure license agreements for diagnostic products could hinder market traction and financial growth.
Market Risks
Risks include failure in clinical development, failure to secure license agreements, and going concern risk.
Market Skepticism
The market is discounting the likelihood of success in human health, despite favorable clinical data and ongoing discussions with potential partners.

VolitionRX (VNRX) vs. SPDR S&P 500 ETF (SPY)

VolitionRX Business Overview & Revenue Model

Company DescriptionVolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
How the Company Makes MoneyVolitionRX generates revenue primarily through the sale of its diagnostic tests, leveraging its Nucleosomics technology to offer innovative solutions for early disease detection. The company's revenue model involves selling these diagnostic products to healthcare providers, laboratories, and potentially through partnerships with larger corporations in the medical diagnostics field. Revenue is also supplemented by collaborations with research institutions and licensing agreements, where VolitionRX partners with other entities to co-develop or distribute their technology, thereby expanding their market reach and sharing in the resulting profits.

VolitionRX Earnings Call Summary

Earnings Call Date:May 15, 2025
(Q1-2025)
|
% Change Since: 64.44%|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment Positive
The earnings call presented several positive developments, including significant revenue growth, reduced operating expenses, and progress in licensing and commercialization efforts across various segments. However, challenges such as a decline in cash position and uncertainties in revenue predictions were noted. Overall, the positive highlights outweigh the lowlights, indicating a promising outlook for the company.
Q1-2025 Updates
Positive Updates
Significant Revenue Growth
VolitionRX reported a 44% increase in revenue compared to Q1 2024, including the first revenue recorded for sales of human products.
Operating Expenses Reduction
Total operating expenses for the quarter declined 35% compared to Q1 2024, reflecting cost reductions across all spending categories.
Successful Licensing Discussions
VolitionRX is in confidential discussions with over 10 companies to license their products, with seven companies having a combined market value exceeding $600 billion.
Nu.Q Platform Developments
The company is progressing in the commercialization of their Nu.Q platform in the human diagnostic market, with potential market opportunities in cancer and sepsis diagnostics.
First Revenue from CE Marked Product
VolitionRX recorded its first revenue from sales of its CE Marked Nu.Q NETs automated product in Europe.
Expansion of Nu.Q Vet
Nu.Q Vet Cancer Test is expanding its global reach, with significant partnerships in place to enhance canine cancer screening.
Nu.Q Discover Revenue Potential
Nu.Q Discover biomarkers are being utilized in a human clinical study sponsored by a leading pharmaceutical company, expected to generate significant revenue.
Negative Updates
Cash Position Decline
Cash and cash equivalents at the end of the quarter totaled approximately $2.6 million compared to $3.3 million at the end of 2024.
Uncertainty in Revenue Predictions
Revenues remain lumpy and difficult to predict from one quarter to the next, leading to the decision not to provide revenue guidance for 2025.
Company Guidance
During VolitionRX Limited's First Quarter 2025 Earnings Conference Call, the company outlined significant financial progress and strategic goals for the year. Operating expenses were reduced by 35% compared to the first quarter of 2024, leading to a 48% decrease in net cash used in operating activities, which totaled $4.3 million. Revenue for the quarter was nearly $0.25 million, marking a 44% increase year-over-year, with the first revenue recorded from human product sales. Cash and cash equivalents were reported at $2.6 million. The company secured $2.3 million from a registered direct offering, $1.6 million in non-dilutive loan financing, and finalized a convertible loan note for $6.25 million for additional financial support. VolitionRX aims to achieve cash flow neutrality for the full year 2025 and is actively pursuing licensing discussions with over 10 companies, targeting a total addressable market of approximately $25 billion annually in cancer and sepsis diagnostics. The company is also making strides in the veterinary market and advancing its Nu.Q Discover program with collaborations in the pharmaceutical sector, which are expected to significantly contribute to revenue growth.

VolitionRX Financial Statement Overview

Summary
VolitionRX is facing significant financial difficulties, evidenced by consistent net losses, negative equity, and reliance on external financing. Despite modest revenue growth, its financial position remains precarious across all financial statements.
Income Statement
35
Negative
VolitionRX's income statement reveals a challenging financial position with consistent net losses. The gross profit margin remains positive at 100% due to low revenue, while net profit margins are significantly negative due to large operating expenses. The revenue growth shows a positive trajectory, increasing by approximately 6.1% in the TTM, yet the company struggles with substantial negative EBIT and EBITDA margins, indicating high operational costs relative to revenue.
Balance Sheet
25
Negative
The balance sheet presents a precarious financial situation with negative stockholders' equity, suggesting the company is heavily leveraged. The debt-to-equity ratio cannot be calculated due to negative equity, but this signifies high financial risk. Total liabilities significantly exceed total assets, indicating potential solvency issues. The low equity ratio further supports the company's weak financial position.
Cash Flow
30
Negative
Cash flow analysis shows VolitionRX faces substantial negative free cash flow, although free cash flow did improve slightly from the previous year. The operating cash flow remains negative, indicating insufficient cash generation from operations to cover expenses. Financing activities have been a primary source of cash, suggesting dependency on external funding to sustain operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.23M775.30K306.39K90.03K13.43K
Gross Profit1.23M775.30K-882.03K90.03K13.43K
EBITDA-25.62M-34.04M-29.24M-25.69M-19.23M
Net Income-26.97M-35.32M-30.27M-26.97M-20.48M
Balance Sheet
Total Assets9.40M27.95M18.30M27.49M26.15M
Cash, Cash Equivalents and Short-Term Investments3.26M20.73M10.87M20.58M19.44M
Total Debt5.82M5.86M4.97M4.02M4.44M
Total Liabilities35.51M36.66M21.42M9.77M9.86M
Stockholders Equity-24.91M-7.80M-2.57M17.94M16.34M
Cash Flow
Free Cash Flow-26.47M-19.15M-16.85M-21.83M-18.41M
Operating Cash Flow-25.89M-18.06M-15.28M-20.85M-16.46M
Investing Cash Flow-573.85K-1.08M-1.57M-973.56K-1.65M
Financing Cash Flow8.66M28.98M6.94M22.86M20.62M

VolitionRX Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.74
Price Trends
50DMA
0.63
Positive
100DMA
0.58
Positive
200DMA
0.61
Positive
Market Momentum
MACD
0.02
Positive
RSI
54.82
Neutral
STOCH
74.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VNRX, the sentiment is Positive. The current price of 0.74 is above the 20-day moving average (MA) of 0.73, above the 50-day MA of 0.63, and above the 200-day MA of 0.61, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 54.82 is Neutral, neither overbought nor oversold. The STOCH value of 74.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VNRX.

VolitionRX Risk Analysis

VolitionRX disclosed 35 risk factors in its most recent earnings report. VolitionRX reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

VolitionRX Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$76.43M138.92%64.15%41.65%
54
Neutral
$35.76M-13.95%
52
Neutral
$7.61B0.04-62.94%2.44%16.14%0.33%
51
Neutral
$88.67M-37.15%-0.26%60.09%
50
Neutral
$9.76M-290.85%78.40%22.41%
45
Neutral
$52.76M-1454.41%35.76%47.48%
41
Neutral
$11.87M-127.82%-24.04%84.11%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VNRX
VolitionRX
0.74
0.05
7.25%
ENZB
Enzo Biochem
0.68
-0.36
-34.62%
BNGO
BioNano Genomics
3.50
-32.60
-90.30%
BNR
Burning Rock Biotech
8.24
1.76
27.16%
BDSX
Biodesix
0.42
-1.24
-74.70%
BIAF
bioAffinity Technologies, Inc.
0.35
-2.33
-86.94%

VolitionRX Corporate Events

Executive/Board ChangesShareholder Meetings
VolitionRX Stockholders Approve Key Proposals at Meeting
Neutral
Jun 20, 2025

At the Annual Meeting on June 18, 2025, VolitionRX‘s stockholders voted on four proposals. The stockholders elected eight members to the Board of Directors, ratified the selection of Sadler, Gibb & Associates, LLC as the independent registered public accounting firm, approved the compensation of the company’s named executive officers, and approved an amendment to the Restated Certificate.

The most recent analyst rating on (VNRX) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025